Research & Literature

Idiopathic aquagenic pruritus: pathogenesis and effective treatment with atenolol.

Cao T, Yong AA, Tan KB, Tey HL

Dermatologic therapy 2015; (28(3)):118-21 doi:10.1111/dth.12194.

Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.

Anderson LA, James G, Duncombe AS, et al.

American journal of hematology 2015; (90(10)):864-70 doi:10.1002/ajh.24098.

Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.

Tefferi A, Barbui T

Mayo Clinic proceedings 2015; (90(9)):1283-93.

Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.

Raedler LA

American health & drug benefits 2015; (8(Spec Feature)):75-9.

Contemporary approach to essential thrombocythemia and polycythemia vera.

Aruch D, Mascarenhas J

Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

Beauverd Y, McLornan DP, Radia DH, Harrison CN

Future oncology (London, England) 2016; (12(6)):739-49 doi:10.2217/fon-2015-0023.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Verstovsek S, Vannucchi AM, Griesshammer M, et al.

Haematologica 2016; (101(7)):821-9 doi:10.3324/haematol.2016.143644.

High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance.

Park CH, Lee KO, Jang JH, et al.

Journal of clinical pathology 2016; (69(8)):737-41 doi:10.1136/jclinpath-2016-203649.

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.

Barbui T, Thiele J, Gisslinger H, et al.

Blood reviews 2016; (30(6)):453-459 doi:10.1016/j.blre.2016.06.001.

Clinical features and management of erythromelalgia: long term follow-up of 46 cases.

Parker LK, Ponte C, Howell KJ, et al.

Clinical and experimental rheumatology 2017; (35(1)):80-84.

Erythromelalgia in patients with essential thrombocythemia and polycythemia vera.

Hou JL, Onajin O, Gangat N, et al.

Leukemia & lymphoma 2017; (58(3)):715-717 doi:10.1080/10428194.2016.1205740.

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, et al.

Haematologica 2017; (102(1)):103-109 doi:10.3324/haematol.2016.152769.

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.

Mesa RA, Miller CB, Thyne M, et al.

Cancer 2017; (123(3)):449-458 doi:10.1002/cncr.30325.

Polycythemia and Thrombocytosis.

Parnes A, Ravi A

Primary care 2016; (43(4)):589-605 doi:10.1016/j.pop.2016.07.011.

From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Vannucchi AM

Haematologica 2017; (102(1)):18-29 doi:10.3324/haematol.2015.129155.

Update from the latest WHO classification of MPNs: a user's manual.

Passamonti F, Maffioli M

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Mesa R, Jamieson C, Bhatia R, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2016; (14(12)):1572-1611 doi:10.6004/jnccn.2016.0169.

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Barbui T, Carobbio A, Ghirardi A, et al.

Haematologica 2017; (102(6)):e219-e221 doi:10.3324/haematol.2017.165126.

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation.

Langabeer SE

EJIFCC 2017; (28(1)):92-93.

Aquagenic cutaneous disorders.

Wang F, Zhao YK, Luo ZY, et al.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2017; (15(6)):602-608 doi:10.1111/ddg.13234.

Low-dose methotrexate in myeloproliferative neoplasm models.

Chinnaiya K, Lawson MA, Thomas S, et al.

Haematologica 2017; (102(9)):e336-e339 doi:10.3324/haematol.2017.165738.

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.

Ghai S, Rai S

South Asian journal of cancer 2017; (6(2)):75-78 doi:10.4103/2278-330X.208854.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(10)):1193-1207.

Secondary erythromelalgia: a tryptophan dietary supplement-induced case associated with elevated 5-hydroxyindoleacetic acid (5HIAA) urinary levels.

Michelerio A, Derlino F, Brazzelli V, Vassallo C

International journal of dermatology 2018; (57(1)):83-85 doi:10.1111/ijd.13760.

Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics.

Lelonek E, Matusiak Ł, Wróbel T, Szepietowski JC

Acta dermato-venereologica 2018; (98(5)):496-500 doi:10.2340/00015555-2906.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, et al.

Leukemia 2018; (32(5)):1057-1069 doi:10.1038/s41375-018-0077-1.

Increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera.

Shin DW, Gu JY, Kim JS, et al.

Clinical hemorheology and microcirculation 2018; (70(1)):59-67 doi:10.3233/CH-170304.

Polycythemia vera: diagnosis, clinical course, and current management

Büyükaşik Y, Alİ R, Ar C, et al.

Turkish journal of medical sciences 2018; (48(4)):698-710 doi:10.3906/sag-1806-43.

Refining the management of polycythemia vera.

Mesa RA

Clinical advances in hematology & oncology : H&O 2018; (16(9)):587-589.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

McMullin MFF, Mead AJ, Ali S, et al.

British journal of haematology 2019; (184(2)):161-175 doi:10.1111/bjh.15647.

Polycythemia Rubra Vera Presenting as Unilateral Clubbing Due to Left Subclavian Artery Thrombosis.

Shiji PV, Narayanan S, Niyaz , George KC

The Journal of the Association of Physicians of India 2018; (66(5)):90-1.

Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan.

Akram AM, Kausar H, Chaudhary A, et al.

Journal of Cancer 2018; (9(23)):4341-4345 doi:10.7150/jca.27414.

Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.

Stefanou MI, Richter H, Härtig F, et al.

European journal of neurology 2019; (26(6)):903-e64 doi:10.1111/ene.13907.

Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

Gordeuk VR, Key NS, Prchal JT

Haematologica 2019; (104(4)):653-658 doi:10.3324/haematol.2018.210732.

Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.

Demuynck T, Verhoef G, Delforge M, et al.

Annals of hematology 2019; (98(6)):1421-1426 doi:10.1007/s00277-019-03654-6.

How I treat polycythemia vera.

Spivak JL

Blood 2019; (134(4)):341-352 doi:10.1182/blood.2018834044.

Ruxolitinib: a targeted treatment option for patients with polycythemia vera.

Vaddi K, Verstovsek S, Kiladjian JJ

Blood and lymphatic cancer : targets and therapy 2016; (6()):7-19 doi:10.2147/BLCTT.S101185.

Cerebral intraparenchymal extramedullary hematopoiesis in polycythemia vera.

Boban J, Kalhs P, Thurnher MM

Acta neurologica Belgica 2020; (120(5)):1181-1183 doi:10.1007/s13760-019-01196-2.

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Yacoub A, Mascarenhas J, Kosiorek H, et al.

Blood 2019; (134(18)):1498-1509 doi:10.1182/blood.2019000428.

Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity.

Frederiksen H, Szépligeti S, Bak M, et al.

Clinical epidemiology 2019; (11()):955-967 doi:10.2147/CLEP.S216787.

Elevated White Blood Cell Levels and Thrombotic Events in Patients With Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data.

Parasuraman S, Yu J, Paranagama D, et al.

Clinical lymphoma, myeloma & leukemia 2020; (20(2)):63-69 doi:10.1016/j.clml.2019.11.010.

Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations.

Segura-Díaz A, Stuckey R, Florido Y, et al.

Cancers 2020; (12(4)) doi:10.3390/cancers12040934.

MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.

Yassin MA, Taher A, Mathews V, et al.

Cancer medicine 2020; (9(13)):4512-4526 doi:10.1002/cam4.3004.

Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera.

Nathany S, Koulmane Laxminarayana SL, Tewari S, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020; (36(3)):477-483 doi:10.1007/s12288-019-01202-w.

Case of aquagenic urticaria: Case report and the results of histopathological examination.

Fukayama M, Domoto Y, Sato S, Asano Y

The Journal of dermatology 2021; (48(1)):88-91 doi:10.1111/1346-8138.15615.

Macroscopic Hematuria as the Initial Presentation of Polycythemia Vera.

Oliveira SCS, Santos LTR, Esmeraldo MA, et al.

Cureus 2020; (12(10)):e10800 doi:10.7759/cureus.10800.

Erythromelalgia Caused by Polycythemia Vera Combined with Primary Aldosteronism.

Suzuki M, Watari T

European journal of case reports in internal medicine 2020; (7(11)):001852 doi:10.12890/2020_001852.

Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.

Wang Z, Liu W, Wang M, et al.

Annals of hematology 2021; (100(2)):465-479 doi:10.1007/s00277-020-04387-7.

[Development of skin squamous cell carcinoma on the scalp in a hydroxycarbamide-treated polycythemia vera patient].

Suzuki M, Maezima E, Ohnuma T, et al.

[Rinsho ketsueki] The Japanese journal of clinical hematology 2020; (61(12)):1670-1672 doi:10.11406/rinketsu.61.1670.

Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Shallis RM, Zeidan AM, Wang R, Podoltsev NA

Hematology/oncology clinics of North America 2021; (35(2)):177-189 doi:10.1016/j.hoc.2020.11.005.

Polycythemia Vera (PV): Update on Emerging Treatment Options.

Benevolo G, Vassallo F, Urbino I, Giai V

Therapeutics and clinical risk management 2021; (17()):209-221 doi:10.2147/TCRM.S213020.

Polycythemia vera as a rare cause of hypertension in a young man.

Vetluzhskaya M, Abramova A, Oganesyan K, Podzolkov V

BMJ case reports 2021; (14(6)) doi:10.1136/bcr-2021-242008.

Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.

Altomare I, Parasuraman S, Paranagama D, et al.

Clinical lymphoma, myeloma & leukemia 2021; (21(11)):e915-e921 doi:10.1016/j.clml.2021.06.023.

Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Dam MJB, Pedersen RK, Knudsen TA, et al.

European journal of haematology 2021; (107(6)):624-633 doi:10.1111/ejh.13700.

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement.

Maslah N, Ravdan O, Drevon L, et al.

British journal of haematology 2022; (196(3)):676-680 doi:10.1111/bjh.17848.

Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.

Le Gall-Ianotto C, Verdet R, Nowak E, et al.

Trials 2021; (22(1)):938 doi:10.1186/s13063-021-05864-8.

Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.

Kanduła Z, Kroll-Balcerzak R, Lewandowski K

Journal of clinical laboratory analysis 2022; (36(5)):e24388 doi:10.1002/jcla.24388.

Genetic Background of Polycythemia Vera.

Regimbeau M, Mary R, Hermetet F, Girodon F

Genes 2022; (13(4)) doi:10.3390/genes13040637.

Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients.

Mori Y, Araki M, Morishita S, et al.

Cancer medicine 2023; (12(2)):1079-1089 doi:10.1002/cam4.4958.

Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.

Edahiro Y, Ito T, Gotoh A, et al.

International journal of hematology 2022; (116(5)):696-711 doi:10.1007/s12185-022-03412-x.

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms.

Shi Z, Liu J, Zhao Y, et al.

Haematologica 2023; (108(5)):1359-1373 doi:10.3324/haematol.2021.280320.

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.

Thiele J, Kvasnicka HM, Orazi A, et al.

American journal of hematology 2023; (98(1)):166-179 doi:10.1002/ajh.26751.

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

Kanduła Z, Janowski M, Więckowska B, et al.

Journal of cancer research and clinical oncology 2023; (149(8)):4789-4803 doi:10.1007/s00432-022-04327-0.

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).

Okikiolu J, Woodley C, Cadman-Davies L, et al.

Leukemia research reports 2023; (19()):100360 doi:10.1016/j.lrr.2022.100360.

Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.

Handa S, Ginzburg Y, Hoffman R, Kremyanskaya M

Current opinion in hematology 2023; (30(2)):45-52 doi:10.1097/MOH.0000000000000747.

Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.

Le Gall-Ianotto C, Ficheux AS, Lippert E, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(6)):1175-1183 doi:10.1111/jdv.18990.

Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.

Kuykendall AT

Annals of hematology 2023; (102(5)):985-993 doi:10.1007/s00277-023-05172-y.

Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases.

Gangat N, Abdallah M, Szuber N, et al.

American journal of hematology 2023; (98(7)):E165-E167 doi:10.1002/ajh.26933.

Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.

Tefferi A, Barbui T

American journal of hematology 2023; (98(9)):1465-1487 doi:10.1002/ajh.27002.

Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.

Skov V, Thomassen M, Kjaer L, et al.

European journal of haematology 2023; (111(5)):805-814 doi:10.1111/ejh.14081.

Naltrexone: a Novel Approach to Pruritus in Polycythemia Vera.

Nikzad N, Jackson LK

Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2023; (40(Suppl 3)):S73-S75 doi:10.12788/fp.0396.

Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.

Benevolo G, Marchetti M, Melchio R, et al.

Vascular health and risk management 2023; (19()):765-778 doi:10.2147/VHRM.S429995.

The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.

Barbui T, Carobbio A, Thiele J, et al.

Blood cancer journal 2023; (13(1)):187 doi:10.1038/s41408-023-00960-1.

SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera.

Masarova L, Chifotides HT

Clinical lymphoma, myeloma & leukemia 2024; (24(3)):141-148 doi:10.1016/j.clml.2023.11.004.

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.

Gerds AT, Mesa R, Burke JM, et al.

Blood 2024; (143(16)):1646-1655 doi:10.1182/blood.2023020232.

Polycythemia Vera: Barriers to and Strategies for Optimal Management.

Duminuco A, Harrington P, Harrison C, Curto-Garcia N

Blood and lymphatic cancer : targets and therapy 2023; (13()):77-90 doi:10.2147/BLCTT.S409443.

A safety evaluation of ruxolitinib for the treatment of polycythemia vera.

Boldrini V, Vannucchi AM, Guglielmelli P

Expert opinion on drug safety 2024; (23(1)):1-7 doi:10.1080/14740338.2023.2299391.

Obstructive Sleep Apnea Does Not Exclude Polycythemia Vera: A Case Report.

Afana MS, Abu-Tineh M, Alshurafa A, et al.

Case reports in oncology 2024; (17(1)):91-95 doi:10.1159/000535742.

Erythrocytosis and CKD: A Review.

Aoun M, Jadoul M, Anders HJ

American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (84(4)):495-506 doi:10.1053/j.ajkd.2024.02.015.

Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians.

Kuykendall AT, Fine JT, Kremyanskaya M

Clinical lymphoma, myeloma & leukemia 2024; (24(8)):512-522 doi:10.1016/j.clml.2024.04.003.

The assessment of health-related quality of life in patients with polycythemia vera.

Doğan EE, Keklik Karadağ F, Aydin D, et al.

Medicine 2024; (103(30)):e38814 doi:10.1097/MD.0000000000038814.

A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera.

Furuya C, Hashimoto Y, Morishita S, et al.

Hematology (Amsterdam, Netherlands) 2024; (29(1)):2427905 doi:10.1080/16078454.2024.2427905.

Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety.

Masarova L, Mascarenhas J, Rampal R, et al.

Cancer 2025; (131(1)):e35661 doi:10.1002/cncr.35661.

The Janus kinase 2 (JAK2) Mutation Burden is Related to Hematological Outcomes in Thai Patients with Myeloproliferative Neoplasms.

Sritana N, Cholnakasem N, Yimyaem M, et al.

Asian Pacific journal of cancer prevention : APJCP 2025; (26(2)):579-586 doi:10.31557/APJCP.2025.26.2.579.

Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes.

Sangiorgio V, Mottadelli F, Pagni F, et al.

International journal of laboratory hematology 2025; (47(5)):869-876 doi:10.1111/ijlh.14476.

The frequency of JAK2 V617F mutation and its association with low EPO levels in polycythemia vera patients.

Aci R, Keskin A, Sezer Ö, et al.

Scandinavian journal of clinical and laboratory investigation 2025; (85(4)):259-262 doi:10.1080/00365513.2025.2502945.

Different Colours of Polycythemia Vera: A Case Series.

Viswanathan N, Adalarasan S, T S, S Y

Cureus 2025; (17(8)):e90913 doi:10.7759/cureus.90913.

Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus.

Witte F, Weisshaar E, Metz M, et al.

Dermatology and therapy 2025; (15(12)):3593-3604 doi:10.1007/s13555-025-01548-2.

Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs).

Ma X, Zhou Z, Gu S, et al.

Cancers 2025; (17(19)) doi:10.3390/cancers17193142.

The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation.

Brown R, Bennett R, Crean C, et al.

British journal of haematology 2025; (207(6)):2597-2601 doi:10.1111/bjh.70198.

Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.

Chew LP, Ginzburg YZ, Kirubamoorthy K, et al.

Leukemia research 2025; (159()):108132 doi:10.1016/j.leukres.2025.108132.

Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.

Nada EA, Elfagieh MA, Abdelsalam F, et al.

Annals of hematology 2025; (104(12)):6131-6145 doi:10.1007/s00277-025-06701-7.

Ropeginterferon alfa-2b in polycythemia vera: redefining disease control through molecular targeting.

De Fazio L, Molica M, Rossi M

Expert review of anticancer therapy 2026; (26(3)):301-306 doi:10.1080/14737140.2025.2592736.

Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study.

Neumark N, Jalowiec KA, Tichelli A, et al.

Annals of hematology 2026; (105(3)):100.

Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

Batyrbekova N, Landtblom AR, Hultcrantz M, et al.

European journal of haematology 2026; (116(6)):850-862 doi:10.1111/ejh.70141.

Polycythemia vera.

Ellis MH, Barbui T, Tefferi A

Mayo Clinic proceedings 2026; (101(5)):826-845 doi:10.1016/j.mayocp.2026.01.008.